Oncolytics Biotech (US:ONCY)2026-03-30 21:29Clinical Development - Pelareorep demonstrated a 33% objective response rate (ORR) in second-line metastatic colorectal cancer (mCRC) compared to approximately 10% with standard-of-care, with a median progression-free survival (PFS) of 16.6 months versus 5.7 months[259]. - In the GOBLET Cohort 4 study for second-line squamous cell carcinoma of the anal canal (SCAC), pelareorep and atezolizumab achieved a 30% ORR, significantly higher than the 13.8% ORR of the current standard of care[263]. - A randomized Phase 2 study for second-line RAS-mutated mCRC patients is expected to initiate in late March 2026, with preliminary data anticipated by year-end[260]. - The company is focusing on advancing pelareorep as a platform immunotherapy for gastrointestinal cancers, with plans for registration-enabled clinical studies in metastatic colorectal cancer and pancreatic cancer[254]. - The company anticipates meeting with the FDA in mid-April 2026 to discuss a registrational study design for second-line or later SCAC in the U.S.[263]. Financial Performance - The company reported a net loss of $28,759 for the year ended December 31, 2025, compared to a net loss of $22,794 in 2024, reflecting an increase of $5,965[284]. - Cash and cash equivalents decreased from $11,079 in 2024 to $5,202 in 2025, indicating a significant reduction in liquidity[294]. - Net cash used in operating activities was $20,112 in 2025, slightly higher than $19,883 in 2024, primarily related to funding R&D activities[295]. - The company recognized a fair value loss of $388 from the SEPA Arrangement after selling 6,650,000 common shares for gross proceeds of $2,348 at an average price of $0.35[291]. - Foreign exchange losses amounted to $106 in 2025, compared to gains of $699 in 2024, reflecting fluctuations in currency exchange rates[292]. Funding and Liquidity - As of December 31, 2025, the company had cash and cash equivalents of $5,202, raising concerns about its ability to continue as a going concern without additional financing[277][255]. - The company expects to continue incurring substantial operating losses until future product sales or licensing fees become sufficient to fund operations[302]. - The company plans to raise additional funds through the sale of common shares or other capital resources, but there is no assurance that additional liquidity will be available under acceptable terms[306]. - If adequate funding is not secured, the company may need to scale back operations, including cost reduction strategies and potentially relinquishing rights to its technology[309]. - The company has approximately $39,002 remaining on its $50,000 ATM facility, which is intended to support near-term capital objectives[304]. Expenses and Obligations - Research and development (R&D) expenses decreased by $2,129 from $15,443 in 2024 to $13,314 in 2025, primarily due to lower clinical trial costs[285]. - General and administrative (G&A) expenses increased by $5,312 from $10,099 in 2024 to $15,411 in 2025, driven by higher public company-related expenses and personnel-related costs[287]. - The company has contractual obligations of approximately $1.248 million related to clinical trial and contract manufacturing programs expected to occur over the next two years[311]. - Clinical trial and manufacturing expenses are significant components of the company's R&D expenses, with payments dependent on achieving certain milestones[315]. Strategic Initiatives - The company is actively evaluating strategic partnership options to support its clinical programs and enhance the development of pelareorep[271]. - Manufacturing capabilities are being expanded to support clinical development, with a cGMP production run executed in 2025 and ongoing process validation activities[272]. - The company has not recognized any deferred tax assets due to a history of losses and uncertainties regarding future taxable income[320]. - The number of outstanding warrants remained at 7,667,050 as of December 31, 2025, with no cash flow impact from changes in their fair value[290]. - The company raised net cash proceeds of $14.115 million from the issuance of 22,999,857 common shares through its ATM offering agreements and SEPA Arrangement for the year ended December 31, 2025[310]. Going Concern - There is substantial doubt about the company's ability to continue as a going concern over the next 12 months due to uncertainties in funding requirements and operational expenditures[307]. - Management's estimates and assumptions regarding capital requirements and financial statements may prove to be incorrect, leading to material variances from expectations[307]. - The company may face dilution of shareholders' ownership interest if additional capital is raised through equity or convertible debt securities[308]. - The company has not entered into any off-balance sheet arrangements as of December 31, 2025[312].